Form 4: Stoke Therapeutics' Chief Medical Officer Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On June 3, 2024, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $0.60 per share.
- On the same day, Ticho sold 9,897 shares at a weighted average price of $15.2127, with prices ranging from $14.75 to $15.73, and an additional 103 shares at $15.78.
- Following these transactions, Ticho directly owns 2,485 shares of Stoke Therapeutics common stock and holds options for 60,000 shares.
- The sales were executed under a Rule 10b5-1 trading plan adopted on September 14, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive under a pre-arranged plan. There is no indication of positive or negative implications for the company.
Future Outlook
NA
Industry Context
Executive stock transactions are common and closely monitored, especially in biotech companies like Stoke Therapeutics. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without concerns about insider trading.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include stock options and restricted stock units to align management's interests with those of shareholders.
- The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in a compliant manner.
- Comparing Ticho's transactions to those of executives at similar-sized biotech companies (e.g., Wave Life Sciences, Sarepta Therapeutics) would provide a benchmark for assessing the magnitude and frequency of his stock sales.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| October 2, 2018 | Initial vesting date for stock options (1/4th of total award). |
| September 14, 2023 | Date of adoption of Rule 10b5-1 trading plan. |
| May 13, 2024 | Date of Limited Power of Attorney execution. |
| June 3, 2024 | Date of stock option exercise and share sales. |
| June 5, 2024 | Date of Form 4 filing. |
| April 2, 2028 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.